Resources

This white paper will provide an explanation to the perverse mixture of brand-name biologic companies’ anti-competitive market access tactics and inadequate incentives that have cost the U.S. health care system billions of dollars in lost savings.

The Association for Accessible Medicines (AAM) Biosimilars Council found that delayed entry of biosimilars due to patenting has cost the U.S. health care system an astounding $7.6 billion in lost savings since 2015.

This paper outlines challenges and recommends actions for policymakers to foster the development of biosimilar insulins for America’s patients.

Download the Biosimilars Council’s whitepaper, where you will learn about challenges bringing a biosimilar to market, reimbursement and market access, building the biosimilars marketplace and much more